Monosialotetrahexosylganglioside sodium combined with hyperbaric oxygen on nervous system development and brain physiology in children with hypoxic ischemic encephalopathy.

To investigate the short-term and long-term clinical effects of monosialotetrahexosylganglioside sodium (GM1) combined with hyperbaric oxygen in neonatal hypoxic ischemic encephalopathy. A total of 80 children with hypoxic ischemic encephalopathy who were admitted to our hospital from January 2016 to March 2018 were selected and divided into the observation group and control group according to a random alphabet method, with 40 cases in each group. Neuron-specific enolase (NSE) and amplitude-integrated electroencephalogram (aEEG) were monitored after treatment in both groups, and the mental development index (MDI) and the psychomotor development index (PDI) of children were evaluated by the Bayley Scales of Infant Development (BSID) 12 months after discharge. The results showed that there were no significant differences in NSE levels and aEEG scores of children with mild severity between the two groups after treatment ( > 0.05). However, in both moderate and severe children, the NSE level and aEEG score in the observation group were significantly lower than that in the control group ( < 0.05). There were no statistically significant differences in MDI and PDI scores of children with mild severity between the two groups after 12 months of treatment ( > 0.05). However, in both moderate and severe children, the MDI and PDI scores in the observation group were significantly higher than that in the control group ( < 0.05). The incidence of adverse reactions in the observation group and the control group were 12.50% and 7.50%, respectively, ( = 0.640). The treatment of neonatal Neonatal hypoxic ischemic encephalopathy (HIE) with GM1 combined with hyperbaric oxygen can significantly improve the short-term and long-term nervous system development and brain physiology in children with moderate and severe HIE.